- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report f...
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 2...
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time REHOVOT, Israel & EDEN PRAIRIE, Minn. , Aug. 19, 2024 /PRNewswire/ -- In a sig...
REHOVOT, Israel & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd. (Nasdaq: SSYS) today announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin® 3D printer. The collaboration between CollPlant and Stratasys i...
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial...
REHOVOT, Israel , July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report...
Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are curren...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.